Preliminary results from a phase I clinical trial show that the first in class MYC inhibitor Omomyc (OMO-103) has few…
Peptomyc
VHIO-led research published in Cancer Research Communications shows that the first-in-class MYC inhibitor Omomyc effectively halts disease progression in metastatic…
